Bicycle Therapeutics appoints Kevin Lee as chief executive

21 September 2015

UK-based Bicycle Therapeutics has appointed Kevin Lee as chief executive officer.

Dr Lee brings more than 20 years of experience in drug discovery and development, and joins from Pfizer (NYSE: PFE) where he was senior vice president and chief scientific officer in the rare disease research unit.

Andrew Sandham, chairman of Bicycle, said: “Kevin is an accomplished leader with a proven track record developing novel biopharmaceuticals and business collaborations across therapeutic areas. His experience in translating emerging science into innovative drugs will be invaluable as we apply our product platform to create a pipeline of new therapeutics in oncology and other therapeutic areas.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK